Business
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
BERLIN, MONHEIM, Germany and WHIPPANY, N.J., June 4, 2019 /PRNewswire/ -- Bayer today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a
About this update from Arvinas, Inc.
[{"type":"text","content":"BERLIN, MONHEIM, Germany and WHIPPANY, N.J., June 4, 2019 /PRNewswire/ -- Bayer today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company based in New Haven, Connecticut. The new life science research partnership uniquely leverages the full potential of Arvinas' novel PROTAC® technology, coupled with leading expertise of Bayer in health and agriculture to develop innovations for the benefit of patients and farmers. \n\n \nArvinas is a pioneer in Proteolysis-Targeting Chimera (PROTAC), which harnesses the naturally occurring protein degradation system of the cell to selectively remove target proteins by proteolysis, the breakdown of proteins into amino acids.\nFor Bayer, which is uniquely positioned in health and agriculture, the collaboration demonstrates the utilization of potential synergies of emerging and converging research across human and plant applications that is unprecedented in the life sciences sector. \nBayer will form an exclusive joint venture as the first company to explore the PROTAC technology in agriculture for crop protection, and at the same time, establish a target-based pharmaceutical research collaboration with Arvinas. In addition, Bayer will make an equity investment to sustain its commitment for the technology. \nAgricultural Joint VentureWithin the framework of the joint venture, the exploration of novel molecular targets to address weeds, insects and/or diseases that threaten crops worldwide will be pioneered. As the technology degrades targets rather than inhibiting them, it offers a completely new category of crop protection applications in agriculture. In addition, PROTACs have the potential to revive crop protection mechanisms that have become ineffective due to resistance. Under the framework of the joint venture, Bayer has committed more than $55 million over six years to translate the new protein degradation technology in agro chemistry and to build an agro-specific PROTAC IP portfolio.\n\"The goal is to utilize the complementary expertise of Bayer and Arvinas to develop novel research discoveries that ultimately deliver new crop protection products for farmers,\" said Dr. Robert Reiter, Member of the Executive Committee of Bayer AG's Crop Science Division and Head of Crop Science Research & Development. \"With this cutting-edge science, we aim to deliv...